BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanazawa T, Misawa K, Carey TE. Galanin receptor subtypes 1 and 2 as therapeutic targets in head and neck squamous cell carcinoma. Expert Opin Ther Targets 2010;14:289-302. [PMID: 20148716 DOI: 10.1517/14728221003598922] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Sánchez ML, Coveñas R. The Galaninergic System: A Target for Cancer Treatment. Cancers 2022;14:3755. [DOI: 10.3390/cancers14153755] [Reference Citation Analysis]
2 Misawa K, Mima M, Satoshi Y, Misawa Y, Imai A, Mochizuki D, Nakagawa T, Kurokawa T, Oguro M, Ishikawa R, Yamaguchi Y, Endo S, Kawasaki H, Kanazawa T, Mineta H. Neuropeptide receptor genes GHSR and NMUR1 are candidate epigenetic biomarkers and predictors for surgically treated patients with oropharyngeal cancer. Sci Rep 2020;10:1007. [PMID: 31974445 DOI: 10.1038/s41598-020-57920-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
3 Kanazawa T, Misawa K, Shinmura K, Misawa Y, Kusaka G, Maruta M, Sasaki T, Watanabe Y, Carey TE. Promoter methylation of galanin receptors as epigenetic biomarkers for head and neck squamous cell carcinomas. Expert Rev Mol Diagn 2019;19:137-48. [PMID: 30640567 DOI: 10.1080/14737159.2019.1567334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
4 Russo D, Merolla F, Varricchio S, Salzano G, Zarrilli G, Mascolo M, Strazzullo V, Di Crescenzo RM, Celetti A, Ilardi G. Epigenetics of oral and oropharyngeal cancers. Biomed Rep 2018;9:275-83. [PMID: 30233779 DOI: 10.3892/br.2018.1136] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
5 Solomon I, Voiculescu VM, Caruntu C, Lupu M, Popa A, Ilie MA, Albulescu R, Caruntu A, Tanase C, Constantin C, Neagu M, Boda D. Neuroendocrine Factors and Head and Neck Squamous Cell Carcinoma: An Affair to Remember. Dis Markers 2018;2018:9787831. [PMID: 29854027 DOI: 10.1155/2018/9787831] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 8.0] [Reference Citation Analysis]
6 Kanazawa T, Misawa K, Fukushima H, Misawa Y, Sato Y, Maruta M, Imayoshi S, Kusaka G, Kawabata K, Mineta H, Carey TE, Nishino H. Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis. Oncol Lett 2018;15:9043-50. [PMID: 29805635 DOI: 10.3892/ol.2018.8525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
7 Misawa K, Imai A, Mochizuki D, Misawa Y, Endo S, Hosokawa S, Ishikawa R, Mima M, Shinmura K, Kanazawa T, Mineta H. Genes encoding neuropeptide receptors are epigenetic markers in patients with head and neck cancer: a site-specific analysis. Oncotarget 2017;8:76318-28. [PMID: 29100314 DOI: 10.18632/oncotarget.19356] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
8 Misawa K, Mochizuki D, Endo S, Mima M, Misawa Y, Imai A, Shinmura K, Kanazawa T, Carey TE, Mineta H. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis: METHYLATION PATTERNS OF THE GAL AND GALR1/2 GENES. Mol Carcinog 2017;56:1107-16. [DOI: 10.1002/mc.22577] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
9 Misawa K, Misawa Y, Kanazawa T, Mochizuki D, Imai A, Endo S, Carey TE, Mineta H. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer. Clin Exp Metastasis 2016;33:187-95. [PMID: 26572146 DOI: 10.1007/s10585-015-9768-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
10 Kanazawa T, Misawa K, Misawa Y, Uehara T, Fukushima H, Kusaka G, Maruta M, Carey TE. G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer? Toxins (Basel) 2015;7:2959-84. [PMID: 26251921 DOI: 10.3390/toxins7082959] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
11 Misawa K, Misawa Y, Kondo H, Mochizuki D, Imai A, Fukushima H, Uehara T, Kanazawa T, Mineta H. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma. PLoS One 2015;10:e0118588. [PMID: 25734919 DOI: 10.1371/journal.pone.0118588] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
12 Uehara T, Kanazawa T, Mizukami H, Uchibori R, Tsukahara T, Urabe M, Kume A, Misawa K, Carey TE, Suzuki M, Ichimura K, Ozawa K. Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells. Cancer Sci 2014;105:72-80. [PMID: 24168112 DOI: 10.1111/cas.12315] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
13 Lleras RA, Smith RV, Adrien LR, Schlecht NF, Burk RD, Harris TM, Childs G, Prystowsky MB, Belbin TJ. Unique DNA methylation loci distinguish anatomic site and HPV status in head and neck squamous cell carcinoma. Clin Cancer Res 2013;19:5444-55. [PMID: 23894057 DOI: 10.1158/1078-0432.CCR-12-3280] [Cited by in Crossref: 60] [Cited by in F6Publishing: 43] [Article Influence: 6.7] [Reference Citation Analysis]
14 Misawa K, Kanazawa T, Misawa Y, Uehara T, Imai A, Takahashi G, Takebayashi S, Cole A, Carey TE, Mineta H. Galanin has tumor suppressor activity and is frequently inactivated by aberrant promoter methylation in head and neck cancer. Transl Oncol 2013;6:338-46. [PMID: 23730414 DOI: 10.1593/tlo.13115] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
15 Misawa K, Kanazawa T, Misawa Y, Imai A, Uehara T, Mochizuki D, Endo S, Takahashi G, Mineta H. Frequent promoter hypermethylation of tachykinin-1 and tachykinin receptor type 1 is a potential biomarker for head and neck cancer. J Cancer Res Clin Oncol 2013;139:879-89. [DOI: 10.1007/s00432-013-1393-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
16 Yamamoto H, Okada R, Iguchi K, Ohno S, Yokogawa T, Nishikawa K, Unno K, Hoshino M, Takeda A. Involvement of plasmin-mediated extracellular activation of progalanin in angiogenesis. Biochem Biophys Res Commun 2013;430:999-1004. [PMID: 23261456 DOI: 10.1016/j.bbrc.2012.11.124] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
17 Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J. Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers. Front Oncol 2012;2:194. [PMID: 23251904 DOI: 10.3389/fonc.2012.00194] [Cited by in Crossref: 42] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
18 Tofighi R, Barde S, Palkovits M, Höög A, Hökfelt T, Ceccatelli S, Hulting A. Galanin and its three receptors in human pituitary adenoma. Neuropeptides 2012;46:195-201. [DOI: 10.1016/j.npep.2012.07.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
19 Kim JC, Lee HC, Cho DH, Choi EY, Cho YK, Ha YJ, Choi PW, Roh SA, Kim SY, Kim YS. Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers. J Cancer Res Clin Oncol 2011;137:1571-80. [PMID: 21850381 DOI: 10.1007/s00432-011-1036-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]